跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Bentley James R.
Associate Professor
Dalhousie University
,
Multidisciplinary
电子邮件
BJ725600
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=15051725600
h-index
h10-index
h5-index
2645
引用
25
H-指数
根据存储在 Pure 中的刊物数量以及来自 PlumX 的引用文献数量进行计算
572
引用
11
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
228
引用
7
H-指数
根据存储在 Pure 中的刊物数量以及来自 PlumX 的引用文献数量进行计算
2004
2023
每年的科研成果
综述
指纹
网络
科研成果
(54)
新闻 / 媒体
(4)
相似简介
(6)
指纹
深入其中 Bentley James R. 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Medicine and Dentistry
Wart Virus
100%
Colposcopy
67%
Cervical Cancer
63%
Cervical Intraepithelial Neoplasia
54%
Cytotechnology
43%
Malignant Neoplasm
39%
Cervical Cancer Prevention
34%
Health Care Cost
34%
Cervical Cancer Screening
33%
Cancer Surgery
31%
Disease
31%
COVID-19
30%
Pandemic
30%
Systematic Review
28%
Adnexal Mass
24%
Patient Referral
24%
Biopsy
22%
Triage
21%
Screening
19%
Uterine Cervix Cytology
19%
Uterine Cervix Dysplasia
19%
Health Technology
17%
Technology Assessment
17%
Oncology
17%
Conservative Treatment
17%
Precancerous Condition
17%
Cancer
16%
Trebananib
15%
Meta-Analysis
15%
Odds Ratio
15%
Survivin
15%
Symptom
15%
Recurrent Ovarian Cancer
15%
Gemcitabine
15%
Complementary and Alternative Medicine
15%
Premature Labor
15%
Endometrial Cancer
15%
Cancer Immunization
15%
Peritoneal Fibrosis
15%
Debulking Surgery
15%
Gestational Trophoblastic Disease
15%
Genotype
12%
Pregnancy
11%
Clinical Trial
10%
Papanicolaou Stain
9%
Randomized Controlled Trial
8%
Preventive Medicine
8%
Observational Study
8%
Medical Specialty
8%
Controlled Clinical Trial
8%
Keyphrases
High-risk Human Papillomavirus (HR-HPV)
35%
Cervical Cancer
33%
Human Papillomavirus Testing
17%
Platinum-resistant Ovarian Cancer
17%
Aptima
17%
Hybrid Capture
17%
Recurring
15%
Multi-regional
15%
Regional Health
15%
Health Economic Analysis
15%
Cancer Vaccination
15%
Confidence Interval
15%
Cancer Prevention Strategies
15%
Ovarian Cancer Patients
15%
Carboplatin
15%
Cervical Intraepithelial Neoplasia Grade 1
15%
Cancer Surgery
15%
Cervical Intraepithelial Neoplasia Grade 2
15%
Trebananib
15%
Ovarian Mass
15%
ENGOT
15%
Adnexal Mass
15%
Prognostic Nomogram
15%
Serous Cancer
15%
Cancer of the Uterus
15%
Primary Screening
15%
Dynamic Scoring
15%
Cervical Cancer Prevention
15%
Cervical Intraepithelial Neoplasia Grade 3
15%
PreTect HPV-Proofer
15%
Targeted Immunotherapy
15%
Survivin
15%
Polyfunctional T Cells
15%
Meta-analysis
15%
Systematic Meta-analysis
15%
Pegylated Liposomal Doxorubicin
15%
COVID-19 Pandemic
15%
Natural History
15%
EORTC
15%
Sclerosing Mesenteritis
15%
Vaccination
15%
Ontario Canada
15%
Screening Algorithm
15%
Phase II Study
15%
Health Economic Model
15%
Glandular Lesions
15%
Related Rates
15%
Gestational Trophoblastic Disease
15%
Hydatidiform Mole
15%
E7 mRNA
15%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
45%
Uterine Cervix Cancer
38%
Carboplatin
30%
Agrotis
19%
Human Papillomavirus
17%
Gemcitabine
15%
Doxorubicin
15%
Uterine Cervix Carcinoma in Situ
15%
Immunotherapy
15%
Trebananib
15%
Premature Labor
15%
Survivin
15%
Peritoneal Fibrosis
15%
Trophoblastic Tumor
15%
Hydatidiform Mole
15%
Human Papillomavirus Type 16
13%
Malignant Neoplasm
12%
Cyclophosphamide
10%
Neoplasm
10%
CD8 Antigen
10%
Infection
7%
Low Birth Weight
7%
Trophoblastic Disease
7%
Prematurity
7%
Paclitaxel
6%
Disease
6%
Adverse Event
6%
Thecoma
5%
Tumor Antigen
5%
Endometrium Carcinoma
5%
Uterine Cervix Dysplasia
5%
Cancer Vaccine
5%
